Format

Send to

Choose Destination
Br J Cancer. 2014 Oct 14;111(8):1469-75. doi: 10.1038/bjc.2013.820.

Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.

Author information

1
1] TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany [2] BioNTech AG, Hölderlinstr 8, 55131 Mainz, Germany.
2
TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany.
3
1] TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany [2] BioNTech AG, Hölderlinstr 8, 55131 Mainz, Germany [3] TheraCode GmbH, Hölderlinstr 8, 55131 Mainz, Germany.
4
1] TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany [2] Ribological GmbH, Hölderlinstr 8, 55130 Mainz, Germany.
5
1] University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany [2] Ganymed Pharmaceuticals AG, Freiligrathstraße 12, 55131 Mainz, Germany.
6
1] TRON gGmbH-Translational Oncology at Johannes Gutenberg-University Medical Center gGmbH, Langenbeckstr 1, Building 708, 55131 Mainz, Germany [2] BioNTech AG, Hölderlinstr 8, 55131 Mainz, Germany [3] University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

Abstract

Cancer is a disease caused by DNA mutations. Cancer therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the mutations in a tumour are unique to that single patient and only a small number of mutations are shared between patients, the addressed medical need is modest. A rapidly determined patient-specific tumour mutation pattern combined with a flexible mutation-targeting drug platform could generate a mutation-targeting individualised therapy, which would benefit each single patient. Next-generation sequencing enables the rapid identification of somatic mutations in individual tumours (the mutanome). Immunoinformatics enables predictions of mutation immunogenicity. Mutation-targeting RNA-based vaccines can be rapidly and affordably synthesised as custom GMP drug products. Integration of these cutting-edge technologies into a clinically applicable process holds the promise of a disruptive innovation benefiting cancer patients. Here, we describe our translation of the individualised RNA-based cancer vaccine concept into clinic trials.

PMID:
25314223
PMCID:
PMC4200076
DOI:
10.1038/bjc.2013.820
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center